1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
1
Active Trials
200 recruiting
6
Rare Diseases
across 12 areas
0
News (30d)
Quiet
Nurix Therapeutics is a company with 1 orphan drug designation across 6 rare diseases. Active clinical trials in 1 indication. 1 active policy bill affects their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Waldenstrom macroglobulinemia | a bifunctional molecule consisting of a Bruton's tyrosine kinase (BTK)-binding hook and cereblon (CRBN)-binding harness, bridged by a chemical linker | Des.TrialAppr. |
| breast cancer | - | Des.TrialAppr. |
| cancer | - | Des.TrialAppr. |
| cervical cancer | - | Des.TrialAppr. |
| lymphoma | - | Des.TrialAppr. |
| ovarian cancer | - | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
61
overlap in 2+ diseases
0/6
candidate diseases
0
avg importance: 0
1
affecting portfolio
0% of portfolio targets high unmet need diseases
61
overlap in 2+ diseases
0/6
candidate diseases
0
avg importance: 0
1
affecting portfolio